Search

Author/Creator Guclu, Salih Z

1. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Issue 8 (August 2015)

Authors:
Soria, Jean-Charles; Felip, Enriqueta; Cobo, Manuel; Lu, Shun; Syrigos, Konstantinos; Lee, Ki Hyeong; Göker, Erdem; Georgoulias, Vassilis; Li, Wei; Isla, Dolores; Guclu, Salih Z; Morabito, Alessandro; Min, Young J; Ardizzoni, Andrea; Gadgeel, Shirish M; Wang, Bushi; Chand, Vikram K; Goss, Glenwood D
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
897
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Issue 8 (August 2015)

Authors:
Soria, Jean-Charles; Felip, Enriqueta; Cobo, Manuel; Lu, Shun; Syrigos, Konstantinos; Lee, Ki Hyeong; Göker, Erdem; Georgoulias, Vassilis; Li, Wei; Isla, Dolores; Guclu, Salih Z; Morabito, Alessandro; Min, Young J; Ardizzoni, Andrea; Gadgeel, Shirish M; Wang, Bushi; Chand, Vikram K; Goss, Glenwoo...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
897
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search